RESEARCH: Vaccines
HVTN 048: A Phase I Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of the EP HIV-1090 DNA Vaccine
BHP048
Principal Investigator: Max Essex
Funding: NIH
Objectives:
- To assess the safety and tolerability of EP HIV-1090 in HIV-1-uninfected humans.
- To evaluate the ability of EP HIV-1090 to induce epitope-specific CD8+ and CD4+ T-cell responses.
Enrollment: June 2003–March 2004
Follow Up: Complete September 2005
| Publications:
Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL. J Immunol. 2004 Aug 1;173(3):1941-50. |